首页> 美国卫生研究院文献>other >At the Crossroads of Cancer Stem Cells Radiation Biology and Radiation Oncology
【2h】

At the Crossroads of Cancer Stem Cells Radiation Biology and Radiation Oncology

机译:在癌症干细胞放射生物学和放射肿瘤学的十字路口

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Reports that a small subset of tumor cells initiate and sustain tumor growth, are resistant to radiation and drugs, and bear specific markers, have lead to an explosion of cancer stem cell research. These reports imply that the evaluation of therapeutic response by changes in tumor volume is misleading, as volume changes reflects the response of the sensitive rather than the resistant tumorgenic cell population. The reports further suggest that the marker based selection of the tumor cell population will facilitate the development of radiation treatment schedules, sensitizers and drugs which specifically target the resistant tumorgenic cells that give rise to treatment failure. This review presents evidence that contests the observations that cancer stem cell markers reliably identify the subset of tumor cells which sustain tumor growth, and that the marker identified population is radioresistant relative to the marker-negative cells. Experimental studies show that cells and tumors that survive large radiation doses are not more radioresistant than unirradiated cells and tumors, and also show that the intrinsic radiosensitivity of unsorted colony forming tumor cells, in combination with the fraction of unsorted tumor cells that are tumor initiating, predicts tumor radiocurability.
机译:有报告称,一小部分肿瘤细胞会启动并维持肿瘤的生长,对放射线和药物具有抵抗力,并带有特定的标志物,导致癌症干细胞研究的爆炸式增长。这些报告暗示通过肿瘤体积变化对治疗反应的评估具有误导性,因为体积变化反映的是敏感而不是耐药的致瘤细胞群体的反应。报告进一步表明,肿瘤细胞群的基于标记的选择将促进放射治疗方案,敏化剂和药物的开发,这些放射治疗方案,敏化剂和药物专门针对引起治疗失败的耐药性致瘤细胞。这篇综述提供了与以下观点相矛盾的证据:癌症干细胞标记物可靠地鉴定出维持肿瘤生长的肿瘤细胞子集,并且标记物鉴定出的群体相对于标记物阴性细胞具有放射抗性。实验研究表明,在大剂量辐射下幸存的细胞和肿瘤的辐射耐受性不比未辐射的细胞和肿瘤强,并且还表明未分类的集落形成肿瘤细胞的固有放射敏感性与肿瘤引发的未分类肿瘤细胞的比例结合在一起,预测肿瘤的放射可固化性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号